|
[1]
|
中国医师协会中西医结合医师分会内分泌与代谢病学专业委员会. 糖尿病肾病病证结合诊疗指南[J]. 中医杂志, 2022, 63(2): 190-197.
|
|
[2]
|
Rossing, P., Caramori, M.L., Chan, J.C.N., Heerspink, H.J.L., Hurst, C., Khunti, K., et al. (2022) KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 102, S1-S127. https://doi.org/10.1016/j.kint.2022.06.008
|
|
[3]
|
de Boer, I.H., Khunti, K., Sadusky, T., Tuttle, K.R., Neumiller, J.J., Rhee, C.M., et al. (2022) Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Kidney International, 102, 974-989. https://doi.org/10.1016/j.kint.2022.08.012
|
|
[4]
|
刘完素. 素问玄机原病式[M]. 石学文, 点校. 沈阳: 辽宁科学技术出版社, 1997.
|
|
[5]
|
刘完素. 三消论[M]//刘河间医学全书. 北京: 中国中医药出版社, 2006: 274-275.
|
|
[6]
|
黄帝内经素问[M]. 田代华, 整理. 北京: 人民卫生出版社, 2005.
|
|
[7]
|
灵枢经[M]. 田代华, 刘更生, 整理. 北京: 人民卫生出版社, 2005.
|
|
[8]
|
张仲景. 金匮要略[M]. 何任, 何若苹, 整理. 北京: 人民卫生出版社, 2005.
|
|
[9]
|
叶天士. 临证指南医案[M]. 北京: 人民卫生出版社, 2006.
|
|
[10]
|
王清任. 医林改错[M]. 北京: 人民卫生出版社, 2005.
|
|
[11]
|
周学海. 读医随笔[M]. 北京: 中国中医药出版社, 2007.
|
|
[12]
|
中华中医药学会, 北京中医药大学东直门医院, 北京中医药大学, 等. 糖尿病肾脏疾病中西医结合诊疗指南[J]. 北京中医药大学学报, 2024, 47(4): 579-591.
|
|
[13]
|
Li, S., Duan, S.W., Dong, Z.Y., et al. (2024) Distribution of Traditional Chinese Medicine Syndromes in Diabetic Kidney Disease Chronic Kidney Disease 1-5: A Correlation Study. Journal of Traditional Chinese Medicine, 44, 572-580.
|
|
[14]
|
莫超, 赵洁, 黄国东. 基于文献的糖尿病肾脏病患者中医证候及证素分布规律研究[J]. 中医杂志, 2023, 64(8): 848-852.
|
|
[15]
|
吴倩, 黄帅, 杨静静. 糖尿病肾病中医证型及相关危险因素分析[J]. 蚌埠医学院学报, 2022, 47(7): 901-904.
|
|
[16]
|
Gao, Y., Li, Z., Wang, Y., Zhang, H., Huang, K., Fu, Y., et al. (2024) Analysis of Clinical Evidence on Traditional Chinese Medicine for the Treatment of Diabetic Nephropathy: A Comprehensive Review with Evidence Mapping. Frontiers in Endocrinology, 15, Article ID: 1324782. https://doi.org/10.3389/fendo.2024.1324782
|
|
[17]
|
Liu, X., Ge, M., Zhai, X., Xiao, Y., Zhang, Y., Xu, Z., et al. (2022) Traditional Chinese Medicine for the Treatment of Diabetic Kidney Disease: A Study-Level Pooled Analysis of 44 Randomized Controlled Trials. Frontiers in Pharmacology, 13, Article ID: 1009571. https://doi.org/10.3389/fphar.2022.1009571
|
|
[18]
|
Zhang, L., Yang, L., Shergis, J., Zhang, L., Zhang, A.L., Guo, X., et al. (2019) Chinese Herbal Medicine for Diabetic Kidney Disease: A Systematic Review and Meta-Analysis of Randomised Placebo-Controlled Trials. BMJ Open, 9, e025653. https://doi.org/10.1136/bmjopen-2018-025653
|
|
[19]
|
倪伟建, 丁海华, 唐丽琴, 等. 小檗碱对糖尿病肾病大鼠肾组织VEGF表达的影响[J]. 中国药理学通报, 2015, 31(6): 795-800.
|
|
[20]
|
张雅晨, 孙建国. 小檗碱预防性治疗糖尿病肾病的研究进展[J]. 药学进展, 2023, 47(3): 217-226.
|
|
[21]
|
刘馨鸿, 郭超, 宋冰, 等. 大黄黄连调控ROS/TXNIP/NLRP3通路改善2型糖尿病小鼠肾损伤的作用机制研究[J]. 中国现代应用药学, 2025, 42(12): 2056-2062.
|
|
[22]
|
Chen, Y., Liu, Q., Shan, Z., Mi, W., Zhao, Y., Li, M., et al. (2019) Catalpol Ameliorates Podocyte Injury by Stabilizing Cytoskeleton and Enhancing Autophagy in Diabetic Nephropathy. Frontiers in Pharmacology, 10, Article No. 1477. https://doi.org/10.3389/fphar.2019.01477
|
|
[23]
|
Cai, S., Chen, J. and Li, Y. (2020) Dioscin Protects against Diabetic Nephropathy by Inhibiting Renal Inflammation through TLR4/NF-κB Pathway in Mice. Immunobiology, 225, Article ID: 151941. https://doi.org/10.1016/j.imbio.2020.151941
|
|
[24]
|
Feng, H., Zhu, X., Tang, Y., Fu, S., Kong, B. and Liu, X. (2021) Astragaloside IV Ameliorates Diabetic Nephropathy in db/db Mice by Inhibiting NLRP3 Inflammasome-Mediated Inflammation. International Journal of Molecular Medicine, 48, Article No. 164. https://doi.org/10.3892/ijmm.2021.4996
|
|
[25]
|
Wang, X., Gao, L., Lin, H., Song, J., Wang, J., Yin, Y., et al. (2018) Mangiferin Prevents Diabetic Nephropathy Progression and Protects Podocyte Function via Autophagy in Diabetic Rat Glomeruli. European Journal of Pharmacology, 824, 170-178. https://doi.org/10.1016/j.ejphar.2018.02.009
|
|
[26]
|
Liu, Y.W., Hao, Y.C., Chen, Y.J., Yin, S., Zhang, M., Kong, L., et al. (2018) Protective Effects of Sarsasapogenin against Early Stage of Diabetic Nephropathy in Rats. Phytotherapy Research, 32, 1574-1582. https://doi.org/10.1002/ptr.6088
|
|
[27]
|
Chen, Y., Chen, J., Jiang, M., Fu, Y., Zhu, Y., Jiao, N., et al. (2020) Loganin and Catalpol Exert Cooperative Ameliorating Effects on Podocyte Apoptosis upon Diabetic Nephropathy by Targeting AGEs RAGE Signaling. Life Sciences, 252, Article ID: 117653. https://doi.org/10.1016/j.lfs.2020.117653
|
|
[28]
|
Qiao, Y., Jiao, H., Wang, F. and Niu, H. (2020) Ophiopogonin D of Ophiopogon japonicus Ameliorates Renal Function by Suppressing Oxidative Stress and Inflammatory Response in Streptozotocin-Induced Diabetic Nephropathy Rats. Brazilian Journal of Medical and Biological Research, 53, e9628. https://doi.org/10.1590/1414-431x20209628
|
|
[29]
|
Li, H., Zheng, J., Wu, Y., Zhou, H., Zeng, S. and Li, Q. (2023) Dendrobium officinale Polysaccharide Decreases Podocyte Injury in Diabetic Nephropathy by Regulating IRS-1/AKT Signal and Promoting Mitophagy. Aging, 15, 10291-10306. https://doi.org/10.18632/aging.205075
|
|
[30]
|
Zhang, B., Zhang, X., Zhang, C., Shen, Q., Sun, G. and Sun, X. (2019) Notoginsenoside R1 Protects db/db Mice against Diabetic Nephropathy via Upregulation of Nrf2-Mediated HO-1 Expression. Molecules, 24, Article No. 247. https://doi.org/10.3390/molecules24020247
|
|
[31]
|
Zhang, C., Yuan, R., Li, S., Huang, G., Sun, K., Pan, J., et al. (2023) Notoginsenoside R1 Protects against Diabetic Nephropathy through TXNIP-NLRP3 Signaling Pathway. Clinical Complementary Medicine and Pharmacology, 3, Article ID: 100100. https://doi.org/10.1016/j.ccmp.2023.100100
|
|
[32]
|
Wang, Y., Chang, J., Qiao, S., Yang, Y., Yun, C., Li, Y., et al. (2024) Salvianolic Acid B Attenuates Diabetic Nephropathy through Alleviating ADORA2B, NALP3 in Flammasome, and NF-κB Activity. Canadian Journal of Physiology and Pharmacology, 102, 318-330. https://doi.org/10.1139/cjpp-2023-0089
|
|
[33]
|
Zhang, J., Li, Y., Zhang, F., Zhang, Y., Zhang, L., Zhao, Y., et al. (2024) Hirudin Delays the Progression of Diabetic Kidney Disease by Inhibiting Glomerular Endothelial Cell Migration and Abnormal Angiogenesis. Biomedicine & Pharmacotherapy, 179, Article ID: 117300. https://doi.org/10.1016/j.biopha.2024.117300
|
|
[34]
|
Ma, R., Liu, L., Liu, X., Wang, Y., Jiang, W. and Xu, L. (2013) Triptolide Markedly Attenuates Albuminuria and Podocyte Injury in an Animal Model of Diabetic Nephropathy. Experimental and Therapeutic Medicine, 6, 649-656. https://doi.org/10.3892/etm.2013.1226
|
|
[35]
|
Ren, L., Wan, R., Chen, Z., Huo, L., Zhu, M., Yang, Y., et al. (2022) Triptolide Alleviates Podocyte Epithelial-Mesenchymal Transition via Kindlin-2 and EMT Related TGF-β/Smad Signaling Pathway in Diabetic Kidney Disease. Applied Biochemistry and Biotechnology, 194, 1000-1012. https://doi.org/10.1007/s12010-021-03661-2
|
|
[36]
|
Liang, D., Mai, H., Ruan, F. and Fu, H. (2021) The Efficacy of Triptolide in Preventing Diabetic Kidney Diseases: A Systematic Review and Meta-Analysis. Frontiers in Pharmacology, 12, Article ID: 728758. https://doi.org/10.3389/fphar.2021.728758
|